MX357166B - Anticuerpos que se unen a notum pectinacetilesterasa. - Google Patents

Anticuerpos que se unen a notum pectinacetilesterasa.

Info

Publication number
MX357166B
MX357166B MX2013005906A MX2013005906A MX357166B MX 357166 B MX357166 B MX 357166B MX 2013005906 A MX2013005906 A MX 2013005906A MX 2013005906 A MX2013005906 A MX 2013005906A MX 357166 B MX357166 B MX 357166B
Authority
MX
Mexico
Prior art keywords
antibodies
notum pectinacetylesterase
pectinacetylesterase
notum
neutralize
Prior art date
Application number
MX2013005906A
Other languages
English (en)
Other versions
MX2013005906A (es
Inventor
Reed Powell David
Hong Seokjoo
Feng Xiao
Joseph Brommage Robert Jr
Landes Gregory
Liu Jeff
George Potter David
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of MX2013005906A publication Critical patent/MX2013005906A/es
Publication of MX357166B publication Critical patent/MX357166B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos que neutralizan Notum Pectinacetilesterasa, así como composiciones que los comprenden, y métodos de uso para tratar enfermedades y trastornos que afectan los huesos.
MX2013005906A 2010-11-24 2011-11-22 Anticuerpos que se unen a notum pectinacetilesterasa. MX357166B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41692710P 2010-11-24 2010-11-24
PCT/US2011/061785 WO2012071381A1 (en) 2010-11-24 2011-11-22 Antibodies to notum pectinacetylesterase

Publications (2)

Publication Number Publication Date
MX2013005906A MX2013005906A (es) 2013-06-28
MX357166B true MX357166B (es) 2018-06-28

Family

ID=46146184

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018001218A MX385858B (es) 2010-11-24 2011-11-22 Anticuerpos que se unen a notum pectinacetilesterasa.
MX2013005906A MX357166B (es) 2010-11-24 2011-11-22 Anticuerpos que se unen a notum pectinacetilesterasa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018001218A MX385858B (es) 2010-11-24 2011-11-22 Anticuerpos que se unen a notum pectinacetilesterasa.

Country Status (21)

Country Link
US (3) US20130302346A1 (es)
EP (1) EP2643019B1 (es)
JP (1) JP6033229B2 (es)
KR (2) KR20180069083A (es)
CN (1) CN103298490B (es)
AU (1) AU2011332007C1 (es)
BR (1) BR112013012858B1 (es)
CA (1) CA2817415C (es)
CO (1) CO6721048A2 (es)
DK (1) DK2643019T3 (es)
ES (1) ES2718849T3 (es)
HU (1) HUE043576T2 (es)
IL (1) IL225876A0 (es)
MX (2) MX385858B (es)
NZ (1) NZ609501A (es)
PL (1) PL2643019T3 (es)
PT (1) PT2643019T (es)
RU (1) RU2013123793A (es)
SG (1) SG189982A1 (es)
WO (1) WO2012071381A1 (es)
ZA (1) ZA201302983B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201506782XA (en) * 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
US8802365B2 (en) * 2011-03-22 2014-08-12 Whitehead Institute For Biomedical Research Methods for identifying candidate modulators of NOTUM activity
AU2013310924B2 (en) * 2012-08-31 2017-08-03 Argenx Bvba Method for producing antibody molecules having inter-species, intra-target cross-reactivity
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
KR102585976B1 (ko) 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
WO2020150282A1 (en) * 2019-01-18 2020-07-23 Askgene Pharma Inc. Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis
CN110317271B (zh) * 2019-07-02 2021-04-30 武汉云克隆科技股份有限公司 一种pinp重组抗体的重/轻链可变区及编码基因和重组抗体
US20240109973A1 (en) * 2020-12-16 2024-04-04 Memorial Sloan Kettering Cancer Center Cd40 binding molecules and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6080576A (en) 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
GB0201808D0 (en) * 2002-01-25 2002-03-13 European Molecular Biology Lab Embl Protein
US20040063924A1 (en) * 2002-01-28 2004-04-01 Y Tom Tang Secreted proteins
ATE528397T1 (de) * 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
SG10201506782XA (en) * 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.

Also Published As

Publication number Publication date
PL2643019T3 (pl) 2019-07-31
CA2817415A1 (en) 2012-05-31
KR20140026334A (ko) 2014-03-05
BR112013012858B1 (pt) 2021-12-07
CN103298490B (zh) 2017-04-26
US20130302346A1 (en) 2013-11-14
ES2718849T3 (es) 2019-07-04
CA2817415C (en) 2020-05-12
DK2643019T3 (en) 2019-04-15
JP6033229B2 (ja) 2016-11-30
ZA201302983B (en) 2017-06-28
EP2643019B1 (en) 2019-01-02
CN103298490A (zh) 2013-09-11
MX2013005906A (es) 2013-06-28
US11059907B2 (en) 2021-07-13
RU2013123793A (ru) 2014-12-27
AU2011332007C1 (en) 2017-03-02
JP2014501513A (ja) 2014-01-23
BR112013012858A2 (pt) 2018-09-04
HUE043576T2 (hu) 2019-08-28
WO2012071381A1 (en) 2012-05-31
KR20180069083A (ko) 2018-06-22
SG189982A1 (en) 2013-06-28
US20160152731A1 (en) 2016-06-02
EP2643019A4 (en) 2014-12-31
IL225876A0 (en) 2013-06-27
MX385858B (es) 2025-03-18
PT2643019T (pt) 2019-04-23
US20190241677A1 (en) 2019-08-08
CO6721048A2 (es) 2013-07-31
EP2643019A1 (en) 2013-10-02
AU2011332007B2 (en) 2016-11-10
NZ609501A (en) 2014-12-24
AU2011332007A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
IN2012DN03883A (es)
PH12017501139A1 (en) Novel modulators and methods of use
EP4450130A3 (en) Formulations of enzalutamide
PH12017500864A1 (en) Anti-notch1 antibodies
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MX394137B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
PH12013500379A1 (en) Notum protein modulators and methods of use
MX2016008448A (es) Conjugados de var2csa-farmaco.
WO2013022991A3 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
EP4414376A3 (en) Novel depsipeptide and uses thereof
MX359769B (es) Metodos para descelularizar huesos.
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2013123249A3 (en) Formulations and methods for treating ear conditions
BR112013012858A2 (pt) anticorpos que se ligam a pectina acetilesterase de notum
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
FG Grant or registration